(Source: Fujifilm Holdings Corporation) June 6, 2013 FUJIFILM Corporation (President: Shigehiro Nakajima) has initiated Phase I clinical trial for the anticancer agent "FF-10501" in patients with relapsed or refractory myelodysplastic syndromes (MDS) in Japan. MDS is a type of hematological malignancies, in which hematopoietic stem cells have disorders to produce sufficient normal blood cells, triggering cytopenias. It is also a refractory disease for some patients with poor...
↧